Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Indivior ( (GB:INDV) ) just unveiled an announcement.
Indivior PLC has appointed Dr. David Wheadon as the new Chair of its Board, effective immediately. Dr. Wheadon brings extensive experience from previous roles at AstraZeneca and other major pharmaceutical organizations. His appointment signals the company’s ongoing commitment to leveraging strong leadership to continue its mission of pioneering treatments for opioid use disorder and delivering value to shareholders and stakeholders. The Board also plans to appoint an additional Non-Executive Director soon, indicating strategic moves to strengthen governance and operational oversight.
More about Indivior
Indivior is a global pharmaceutical company focused on developing treatments for substance use disorders (SUD), aiming to transform these from a global crisis to recognized chronic diseases. Headquartered in Richmond, VA, the company employs over 1,000 individuals and offers products in more than 30 countries.
YTD Price Performance: -6.25%
Average Trading Volume: 300,003
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.19B
For detailed information about INDV stock, go to TipRanks’ Stock Analysis page.
